Korean J Ophthalmol.  2015 Apr;29(2):131-137. 10.3341/kjo.2015.29.2.131.

Efficacy of the Mineral Oil and Hyaluronic Acid Mixture Eye Drops in Murine Dry Eye

Affiliations
  • 1Department of Ophthalmology and Research Institute of Medical Sciences, Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, Korea. kcyoon@jnu.ac.kr
  • 2Kim's Eye Clinic of the 21st Century, Seoul, Korea.
  • 3Department of Anatomy, Chonnam National University Medical School, Gwangju, Korea.

Abstract

PURPOSE
To investigate the therapeutic effects of mineral oil (MO) and hyaluronic acid (HA) mixture eye drops on the tear film and ocular surface in a mouse model of experimental dry eye (EDE).
METHODS
Eye drops consisting of 0.1% HA alone or mixed with 0.1%, 0.5%, or 5.0% MO were applied to desiccating stress-induced murine dry eyes. Tear volume, corneal irregularity score, tear film break-up time (TBUT), and corneal fluorescein staining scores were measured at 5 and 10 days after treatment. Ten days after treatment, goblet cells in the conjunctiva were counted after Periodic acid-Schiff staining.
RESULTS
There was no significant difference in the tear volume between desiccating stress-induced groups. The corneal irregularity score was lower in the 0.5% MO group compared with the EDE and HA groups. The 0.5% and 5.0% MO groups showed a significant improvement in TBUT compared with the EDE group. Mice treated with 0.1% and 0.5% MO mixture eye drops showed a significant improvement in fluorescein staining scores compared with the EDE group and the HA group. The conjunctival goblet cell count was higher in the 0.5% MO group compared with the EDE group and HA group.
CONCLUSIONS
The MO and HA mixture eye drops had a beneficial effect on the tear films and ocular surface of murine dry eye. The application of 0.5% MO and 0.1% HA mixture eye drops could improve corneal irregularity, the corneal fluorescein staining score, and conjunctival goblet cell count compared with 0.1% HA eye drops in the treatment of EDE.

Keyword

Dry eye; Hyaluronic acid; Mineral oil; Ocular surface

MeSH Terms

Animals
Conjunctiva/*drug effects/pathology
Cornea/metabolism
Disease Models, Animal
Drug Combinations
Dry Eye Syndromes/*drug therapy/metabolism
Emollients/administration & dosage
Female
Goblet Cells/drug effects/metabolism/pathology
Hyaluronic Acid/*administration & dosage
Mice
Mice, Inbred C57BL
Mineral Oil/*administration & dosage
Ophthalmic Solutions
Tears/*metabolism
Viscosupplements/administration & dosage
Drug Combinations
Emollients
Hyaluronic Acid
Mineral Oil
Ophthalmic Solutions
Viscosupplements

Figure

  • Fig. 1 Mean corneal irregularity scores (A) and representative figure (B) in the untreated (UT), experimental dry eye (EDE), hyaluronic acid (HA), mixed 0.1% mineral oil (MO), mixed 0.5% MO, and mixed 5.0% MO groups at 5 and 10 days after desiccating stress. *p < 0.05 compared with the EDE group; †p < 0.05 compared with the HA group.

  • Fig. 2 Tear film break-up time in the untreated (UT), experimental dry eye (EDE), hyaluronic acid (HA), mixed 0.1% mineral oil (MO), mixed 0.5% MO, and mixed 5.0% MO groups at 5 and 10 days after desiccating stress. *p < 0.05 compared with the EDE group; †p < 0.05 compared with the HA group.

  • Fig. 3 Corneal fluorescein staining scores (A) and representative figure (B) in the untreated (UT), experimental dry eye (EDE), hyaluronic acid (HA), mixed 0.1% mineral oil (MO), mixed 0.5% MO, and mixed 5.0% MO groups at 5 and 10 days after desiccating stress. *p < 0.05 compared with the EDE group; †p < 0.05 compared with the HA group.

  • Fig. 4 Mean goblet cell count (A) and representative figures (B) of the untreated (UT), experimental dry eye (EDE), hyaluronic acid (HA), mixed 0.1% mineral oil (MO), mixed 0.5% MO, and mixed 5.0% MO groups at 10 days after desiccating stress. *p < 0.05 compared with the EDE group; †p < 0.05 compared with the HA group. Sections were stained with periodic acid-Schiff.


Cited by  1 articles

Comparison of Eye Protection Methods of Ointment Instillation under General Anesthesia
Seung Hoon Yoo, Hyuna A Kim, Sang Il Ahn, Soon Im Kim, Jin Kwon Chung
J Korean Ophthalmol Soc. 2015;56(7):1012-1019.    doi: 10.3341/jkos.2015.56.7.1012.


Reference

1. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007; 5:75–92. PMID: 17508116.
2. Cuevas M, Gonzalez-Garcia MJ, Castellanos E, et al. Correlations among symptoms, signs, and clinical tests in evaporative-type dry eye disease caused by Meibomian gland dysfunction (MGD). Curr Eye Res. 2012; 37:855–863. PMID: 22632103.
Article
3. Gupta H, Jain S, Mathur R, et al. Sustained ocular drug delivery from a temperature and pH triggered novel in situ gel system. Drug Deliv. 2007; 14:507–515. PMID: 18027180.
Article
4. Behrens A, Doyle JJ, Stern L, et al. Dysfunctional tear syndrome: a Delphi approach to treatment recommendations. Cornea. 2006; 25:900–907. PMID: 17102664.
5. McCann LC, Tomlinson A, Pearce EI, Papa V. Effectiveness of artificial tears in the management of evaporative dry eye. Cornea. 2012; 31:1–5. PMID: 21968605.
Article
6. McDonald CC, Kaye SB, Figueiredo FC, et al. A randomised, crossover, multicentre study to compare the performance of 0.1% (w/v) sodium hyaluronate with 1.4% (w/v) polyvinyl alcohol in the alleviation of symptoms associated with dry eye syndrome. Eye (Lond). 2002; 16:601–607. PMID: 12194076.
Article
7. Wysenbeek YS, Loya N, Ben Sira I, et al. The effect of sodium hyaluronate on the corneal epithelium. An ultrastructural study. Invest Ophthalmol Vis Sci. 1988; 29:194–199. PMID: 3338879.
8. Sand BB, Marner K, Norn MS. Sodium hyaluronate in the treatment of keratoconjunctivitis sicca A double masked clinical trial. Acta Ophthalmol (Copenh). 1989; 67:181–183. PMID: 2658462.
9. DeLuise VP, Peterson WS. The use of topical Healon tears in the management of refractory dry-eye syndrome. Ann Ophthalmol. 1984; 16:823–824. PMID: 6508097.
10. Stuart JC, Linn JG. Dilute sodium hyaluronate (Healon) in the treatment of ocular surface disorders. Ann Ophthalmol. 1985; 17:190–192. PMID: 3873200.
11. Rawlings AV, Lombard KJ. A review on the extensive skin benefits of mineral oil. Int J Cosmet Sci. 2012; 34:511–518. PMID: 22994201.
Article
12. Wang IJ, Lin IC, Hou YC, Hu FR. A comparison of the effect of carbomer-, cellulose- and mineral oil-based artificial tear formulations. Eur J Ophthalmol. 2007; 17:151–159. PMID: 17415686.
Article
13. Yoon KC, De Paiva CS, Qi H, et al. Desiccating environmental stress exacerbates autoimmune lacrimal keratoconjunctivitis in non-obese diabetic mice. J Autoimmun. 2008; 30:212–221. PMID: 17988834.
Article
14. Niederkorn JY, Stern ME, Pflugfelder SC, et al. Desiccating stress induces T cell-mediated Sjogren’s Syndrome-like lacrimal keratoconjunctivitis. J Immunol. 2006; 176:3950–3957. PMID: 16547229.
15. De Paiva CS, Corrales RM, Villarreal AL, et al. Corticosteroid and doxycycline suppress MMP-9 and inflammatory cytokine expression, MAPK activation in the corneal epithelium in experimental dry eye. Exp Eye Res. 2006; 83:526–535. PMID: 16643899.
Article
16. De Paiva CS, Villarreal AL, Corrales RM, et al. Dry eye-induced conjunctival epithelial squamous metaplasia is modulated by interferon-gamma. Invest Ophthalmol Vis Sci. 2007; 48:2553–2560. PMID: 17525184.
17. Villareal AL, Farley W, Pflugfelder SC. Effect of topical ophthalmic epinastine and olopatadine on tear volume in mice. Eye Contact Lens. 2006; 32:272–276. PMID: 17099387.
Article
18. Li Z, Choi W, Oh HJ, Yoon KC. Effectiveness of topical infliximab in a mouse model of experimental dry eye. Cornea. 2012; 31(Suppl 1):S25–S31. PMID: 23038030.
Article
19. Li Z, Woo JM, Chung SW, et al. Therapeutic effect of topical adiponectin in a mouse model of desiccating stress-induced dry eye. Invest Ophthalmol Vis Sci. 2013; 54:155–162. PMID: 23211823.
Article
20. De Paiva CS, Corrales RM, Villarreal AL, et al. Apical corneal barrier disruption in experimental murine dry eye is abrogated by methylprednisolone and doxycycline. Invest Ophthalmol Vis Sci. 2006; 47:2847–2856. PMID: 16799024.
Article
21. Dogru M, Erturk H, Shimazaki J, et al. Tear function and ocular surface changes with topical mitomycin (MMC) treatment for primary corneal intraepithelial neoplasia. Cornea. 2003; 22:627–639. PMID: 14508259.
Article
22. Xiao X, He H, Lin Z, et al. Therapeutic effects of epidermal growth factor on benzalkonium chloride-induced dry eye in a mouse model. Invest Ophthalmol Vis Sci. 2012; 53:191–197. PMID: 22159022.
Article
23. Vogel R, Crockett RS, Oden N, et al. Demonstration of efficacy in the treatment of dry eye disease with 0.18% sodium hyaluronate ophthalmic solution (vismed, rejena). Am J Ophthalmol. 2010; 149:594–601. PMID: 20346777.
Article
24. Brignole F, Pisella PJ, Dupas B, et al. Efficacy and safety of 0.18% sodium hyaluronate in patients with moderate dry eye syndrome and superficial keratitis. Graefes Arch Clin Exp Ophthalmol. 2005; 243:531–538. PMID: 15965673.
Article
25. Nakamura M, Hikida M, Nakano T. Concentration and molecular weight dependency of rabbit corneal epithelial wound healing on hyaluronan. Curr Eye Res. 1992; 11:981–986. PMID: 1451529.
Article
26. Stern ME, Beuerman RW, Fox RI, et al. The pathology of dry eye: the interaction between the ocular surface and lacrimal glands. Cornea. 1998; 17:584–589. PMID: 9820935.
27. Adamia S, Maxwell CA, Pilarski LM. Hyaluronan and hyaluronan synthases: potential therapeutic targets in cancer. Curr Drug Targets Cardiovasc Haematol Disord. 2005; 5:3–14. PMID: 15720220.
Article
28. Turino GM, Cantor JO. Hyaluronan in respiratory injury and repair. Am J Respir Crit Care Med. 2003; 167:1169–1175. PMID: 12714341.
Article
29. Toole BP. Hyaluronan promotes the malignant phenotype. Glycobiology. 2002; 12:37R–42R.
Article
30. Lerner LE, Schwartz DM, Hwang DG, et al. Hyaluronan and CD44 in the human cornea and limbal conjunctiva. Exp Eye Res. 1998; 67:481–484. PMID: 9820796.
Article
31. Sullivan LJ, McCurrach F, Lee S, et al. Efficacy and safety of 0.3% carbomer gel compared to placebo in patients with moderate-to-severe dry eye syndrome. Ophthalmology. 1997; 104:1402–1408. PMID: 9307633.
Article
32. Wang TJ, Wang IJ, Ho JD, et al. Comparison of the clinical effects of carbomer-based lipid-containing gel and hydroxypropyl-guar gel artificial tear formulations in patients with dry eye syndrome: a 4-week, prospective, open-label, randomized, parallel-group, noninferiority study. Clin Ther. 2010; 32:44–52. PMID: 20171410.
Article
33. Holly FJ. Artificial tear formulations. Int Ophthalmol Clin. 1980; 20:171–184. PMID: 6998897.
Article
34. Scifo C, Barabino S, De Pasquale G, et al. Effects of a new lipid tear substitute in a mouse model of dry eye. Cornea. 2010; 29:802–806. PMID: 20489574.
Article
Full Text Links
  • KJO
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr